NAMS MENOPAUSE CERTIFICATION PRACTICE
EXAMINATION
Comprehensive 200-Question Board Review with Evidence-Based
Rationales
Question 1 (Physiology & Endocrinology)
A 48-year-old woman presents with irregular menses, skipping periods
by 2 to 3 months, and experiencing new-onset sleep disturbance and
mild hot flashes. Her FSH level is tested and found to be elevated.
According to the STRAW+10 staging system, which stage best
characterizes her transition?
A) Stage -3b (Late Reproductive)
B) Stage -2 (Early Menopausal Transition)
C) Stage -1 (Late Menopausal Transition)
D) Stage +1a (Early Postmenopause)
Correct Answer: C
Rationale: The Stages of Reproductive Aging Workshop + 10
(STRAW+10) classifies Stage -1 (Late Menopausal Transition) by
persistent differences in cycle length of 7 days or more (e.g., an interval
of 60 days or more between periods) and elevated FSH levels. Stage -2
(Early Transition) is characterized by persistent cycle length differences
of 7 days or more but without skipped intervals of 60+ days.
Question 2 (Physiology & Endocrinology)
Which of the following neuroendocrine changes is considered the
primary central trigger initiating the menopausal transition and the surge
of GnRH pulse frequency?
, A) Upregulation of hypothalamic kisspeptin-neurokinin B-dynorphin
(KNDy) neurons
B) Hypertrophy of the anterior pituitary lactotroph cells
C) Downregulation of central aromatase activity in the hippocampus
D) Depletion of adrenal dehydroepiandrosterone (DHEA) reserves
Correct Answer: A
Rationale: KNDy (kisspeptin, neurokinin B, and dynorphin) neurons in
the infundibular nucleus of the hypothalamus hypertrophy and alter
their secretory pattern following ovarian follicular atresia and estrogen
withdrawal. This drive is central to generating GnRH pulsatility and
mediating thermoregulatory changes (hot flashes).
Question 3 (Vasomotor Symptoms)
A 53-year-old postmenopausal woman with severe vasomotor symptoms
(VMS) and a history of estrogen-receptor positive (ER+) breast cancer
treated with lumpectomy and tamoxifen 3 years ago desires non-
hormonal pharmacotherapy. Which of the following is the FDA-
approved non-hormonal agent specifically indicated for moderate-to-
severe VMS associated with menopause?
A) Paroxetine mesylate
B) Venlafaxine extended-release
C) Gabapentin
D) Clonidine transdermal
Correct Answer: A
Rationale: Paroxetine mesylate 7.5 mg is the only selective serotonin
reuptake inhibitor (SSRI) specifically FDA-approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause.
Furthermore, paroxetine is a potent CYP2D6 inhibitor and should be
avoided in women taking tamoxifen because it blocks the conversion of
,tamoxifen to its active metabolite, endoxifen. However, venlafaxine,
citalopram, and escitalopram are safe with tamoxifen.
Question 4 (Vasomotor Symptoms)
A 51-year-old woman taking tamoxifen for breast cancer experiences
severe hot flashes. Which non-hormonal treatment option should be
avoided due to significant drug-drug interaction reducing tamoxifen
efficacy?
A) Venlafaxine
B) Paroxetine
C) Gabapentin
D) Escitalopram
Correct Answer: B
Rationale: Paroxetine is a potent inhibitor of CYP2D6, the hepatic
enzyme responsible for metabolizing tamoxifen into its active metabolite,
endoxifen. Coadministration significantly reduces endoxifen levels and
may increase breast cancer recurrence risk. Venlafaxine and
escitalopram are weak inhibitors of CYP2D6 and are considered safe.
Question 5 (Genitourinary Syndrome of Menopause (GSM))
A 60-year-old postmenopausal woman presents with vaginal dryness,
dyspareunia, and recurrent urinary tract infections. Pelvic examination
reveals pallor, loss of vaginal rugae, and urethral meatal eversion. She
has a history of treated breast cancer 5 years ago and remains concerned
about systemic absorption of estrogen. Which of the following is the
most appropriate first-line therapy?
A) Ospemifene oral tablets
B) Ultra-low-dose vaginal estrogen (e.g., estradiol vaginal rings or
low-dose inserts)
C) Over-the-counter vaginal lubricants and moisturizers
, D) Systemic conjugated equine estrogens with medroxyprogesterone
acetate
Correct Answer: C
Rationale: For women with a history of breast cancer experiencing
GSM, non-hormonal vaginal lubricants and moisturizers are the initial
first-line recommendation. If symptoms persist, non-hormonal therapies
such as vaginal laser therapy or consultation with oncology regarding
ultra-low-dose vaginal estrogen (which results in minimal systemic
absorption) can be considered, but non-hormonal
lubricants/moisturizers remain the standard starting point.
Question 6 (Genitourinary Syndrome of Menopause (GSM))
A 56-year-old woman complains of moderate dyspareunia and vaginal
dryness. She is in good health and has no history of estrogen-dependent
cancers. Her clinician prescribes a selective estrogen receptor modulator
(SERM) approved for the treatment of moderate-to-severe dyspareunia
associated with postmenopausal GSM. What is this medication?
A) Raloxifene
B) Ospemifene
C) Bazedoxifene
D) Tamoxifen
Correct Answer: B
Rationale: Ospemifene is an oral SERM approved for the treatment of
moderate-to-severe dyspareunia and/or moderate-to-severe vaginal
dryness due to postmenopausal GSM. It acts as an estrogen agonist on
vaginal epithelium and bone, while having neutral or antagonistic
effects on breast tissue.
Question 7 (Bone Health & Osteoporosis)
EXAMINATION
Comprehensive 200-Question Board Review with Evidence-Based
Rationales
Question 1 (Physiology & Endocrinology)
A 48-year-old woman presents with irregular menses, skipping periods
by 2 to 3 months, and experiencing new-onset sleep disturbance and
mild hot flashes. Her FSH level is tested and found to be elevated.
According to the STRAW+10 staging system, which stage best
characterizes her transition?
A) Stage -3b (Late Reproductive)
B) Stage -2 (Early Menopausal Transition)
C) Stage -1 (Late Menopausal Transition)
D) Stage +1a (Early Postmenopause)
Correct Answer: C
Rationale: The Stages of Reproductive Aging Workshop + 10
(STRAW+10) classifies Stage -1 (Late Menopausal Transition) by
persistent differences in cycle length of 7 days or more (e.g., an interval
of 60 days or more between periods) and elevated FSH levels. Stage -2
(Early Transition) is characterized by persistent cycle length differences
of 7 days or more but without skipped intervals of 60+ days.
Question 2 (Physiology & Endocrinology)
Which of the following neuroendocrine changes is considered the
primary central trigger initiating the menopausal transition and the surge
of GnRH pulse frequency?
, A) Upregulation of hypothalamic kisspeptin-neurokinin B-dynorphin
(KNDy) neurons
B) Hypertrophy of the anterior pituitary lactotroph cells
C) Downregulation of central aromatase activity in the hippocampus
D) Depletion of adrenal dehydroepiandrosterone (DHEA) reserves
Correct Answer: A
Rationale: KNDy (kisspeptin, neurokinin B, and dynorphin) neurons in
the infundibular nucleus of the hypothalamus hypertrophy and alter
their secretory pattern following ovarian follicular atresia and estrogen
withdrawal. This drive is central to generating GnRH pulsatility and
mediating thermoregulatory changes (hot flashes).
Question 3 (Vasomotor Symptoms)
A 53-year-old postmenopausal woman with severe vasomotor symptoms
(VMS) and a history of estrogen-receptor positive (ER+) breast cancer
treated with lumpectomy and tamoxifen 3 years ago desires non-
hormonal pharmacotherapy. Which of the following is the FDA-
approved non-hormonal agent specifically indicated for moderate-to-
severe VMS associated with menopause?
A) Paroxetine mesylate
B) Venlafaxine extended-release
C) Gabapentin
D) Clonidine transdermal
Correct Answer: A
Rationale: Paroxetine mesylate 7.5 mg is the only selective serotonin
reuptake inhibitor (SSRI) specifically FDA-approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause.
Furthermore, paroxetine is a potent CYP2D6 inhibitor and should be
avoided in women taking tamoxifen because it blocks the conversion of
,tamoxifen to its active metabolite, endoxifen. However, venlafaxine,
citalopram, and escitalopram are safe with tamoxifen.
Question 4 (Vasomotor Symptoms)
A 51-year-old woman taking tamoxifen for breast cancer experiences
severe hot flashes. Which non-hormonal treatment option should be
avoided due to significant drug-drug interaction reducing tamoxifen
efficacy?
A) Venlafaxine
B) Paroxetine
C) Gabapentin
D) Escitalopram
Correct Answer: B
Rationale: Paroxetine is a potent inhibitor of CYP2D6, the hepatic
enzyme responsible for metabolizing tamoxifen into its active metabolite,
endoxifen. Coadministration significantly reduces endoxifen levels and
may increase breast cancer recurrence risk. Venlafaxine and
escitalopram are weak inhibitors of CYP2D6 and are considered safe.
Question 5 (Genitourinary Syndrome of Menopause (GSM))
A 60-year-old postmenopausal woman presents with vaginal dryness,
dyspareunia, and recurrent urinary tract infections. Pelvic examination
reveals pallor, loss of vaginal rugae, and urethral meatal eversion. She
has a history of treated breast cancer 5 years ago and remains concerned
about systemic absorption of estrogen. Which of the following is the
most appropriate first-line therapy?
A) Ospemifene oral tablets
B) Ultra-low-dose vaginal estrogen (e.g., estradiol vaginal rings or
low-dose inserts)
C) Over-the-counter vaginal lubricants and moisturizers
, D) Systemic conjugated equine estrogens with medroxyprogesterone
acetate
Correct Answer: C
Rationale: For women with a history of breast cancer experiencing
GSM, non-hormonal vaginal lubricants and moisturizers are the initial
first-line recommendation. If symptoms persist, non-hormonal therapies
such as vaginal laser therapy or consultation with oncology regarding
ultra-low-dose vaginal estrogen (which results in minimal systemic
absorption) can be considered, but non-hormonal
lubricants/moisturizers remain the standard starting point.
Question 6 (Genitourinary Syndrome of Menopause (GSM))
A 56-year-old woman complains of moderate dyspareunia and vaginal
dryness. She is in good health and has no history of estrogen-dependent
cancers. Her clinician prescribes a selective estrogen receptor modulator
(SERM) approved for the treatment of moderate-to-severe dyspareunia
associated with postmenopausal GSM. What is this medication?
A) Raloxifene
B) Ospemifene
C) Bazedoxifene
D) Tamoxifen
Correct Answer: B
Rationale: Ospemifene is an oral SERM approved for the treatment of
moderate-to-severe dyspareunia and/or moderate-to-severe vaginal
dryness due to postmenopausal GSM. It acts as an estrogen agonist on
vaginal epithelium and bone, while having neutral or antagonistic
effects on breast tissue.
Question 7 (Bone Health & Osteoporosis)
